The weight-loss drug innovator is falling behind in the industry and facing major pricing pressures.

Historical evidence indicates that abrupt market fluctuations can affect any corporation, regardless of its perceived dominance.

Eli Lilly's decision to reduce the price of its popular weight loss drug makes more sense than it appears at first. The company still has a robust business that is delivering excellent results and ...

Investors worried that the company could take quite a revenue hit due to a competitor's move.

Novo’s CagriSema shot was shown to be less effective than rival Lilly’s tirzepatide ...

In recent developments, Eli Lilly reported sustained efficacy for its inflammatory bowel disease treatment Omvoh over three years in patients with moderate-to-severe Crohn's disease. Early results ...

A robust pipeline is essential for a buy-and-hold pharmaceutical stock.